Efficacy of anti-PD1 drugs nivolumab or pembrolizumab in pateints with metastatic uveal melanoma

Trial Profile

Efficacy of anti-PD1 drugs nivolumab or pembrolizumab in pateints with metastatic uveal melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2016 New trial record
    • 07 Jun 2016 Results (n=21) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top